Vivoryon Therapeutics N.V. (0R3M.L)
EUR 1.66
(-2.24%)
EUR 1.66
(-2.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -18.52 Million EUR | 29.89% |
| 2022 | -26.42 Million EUR | -83.02% |
| 2021 | -14.43 Million EUR | 44.46% |
| 2020 | -25.99 Million EUR | 36.79% |
| 2019 | -41.11 Million EUR | -1086815.15% |
| 2018 | -3783.00 EUR | 63.24% |
| 2017 | -10.29 Thousand EUR | 53.0% |
| 2016 | -21.89 Thousand EUR | -2.51% |
| 2015 | -21.36 Thousand EUR | -2.11% |
| 2014 | -20.92 Thousand EUR | -104.48% |
| 2013 | 467 Thousand EUR | 106.04% |
| 2012 | -7.72 Million EUR | 16.88% |
| 2011 | -9.29 Million EUR | -53.36% |
| 2010 | -6.06 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -15.26 Million EUR | 0.0% |
| 2023 Q4 | -18.52 Million EUR | 0.0% |
| 2023 Q2 | -29.49 Million EUR | 0.0% |
| 2023 FY | -18.52 Million EUR | 29.89% |
| 2022 Q2 | -24.2 Million EUR | 0.0% |
| 2022 FY | -26.42 Million EUR | -83.02% |
| 2022 Q4 | -26.42 Million EUR | 0.0% |
| 2021 FY | -14.43 Million EUR | 44.46% |
| 2021 Q2 | -19.56 Million EUR | 0.0% |
| 2021 Q4 | -14.43 Million EUR | 0.0% |
| 2020 Q4 | -25.99 Million EUR | 0.0% |
| 2020 FY | -25.99 Million EUR | 36.79% |
| 2020 Q2 | -3.26 Million EUR | 0.0% |
| 2019 FY | -41.11 Million EUR | -1086815.15% |
| 2019 Q4 | -41.11 Million EUR | 0.0% |
| 2019 Q2 | -7.82 Million EUR | 0.0% |
| 2018 FY | -3783.00 EUR | 63.24% |
| 2018 Q2 | -6686.00 EUR | 0.0% |
| 2018 Q4 | -3783.00 EUR | 0.0% |
| 2017 Q2 | -14.38 Thousand EUR | 0.0% |
| 2017 FY | -10.29 Thousand EUR | 53.0% |
| 2017 Q4 | -10.29 Thousand EUR | 0.0% |
| 2016 Q4 | -21.89 Thousand EUR | 0.0% |
| 2016 Q2 | -14.24 Thousand EUR | 0.0% |
| 2016 FY | -21.89 Thousand EUR | -2.51% |
| 2015 Q2 | -14.79 Thousand EUR | 0.0% |
| 2015 Q4 | -21.36 Thousand EUR | 0.0% |
| 2015 FY | -21.36 Thousand EUR | -2.11% |
| 2014 Q2 | 9.61 Million EUR | 0.0% |
| 2014 Q4 | -20.92 Thousand EUR | 0.0% |
| 2014 FY | -20.92 Thousand EUR | -104.48% |
| 2013 Q4 | 467 Thousand EUR | 0.0% |
| 2013 FY | 467 Thousand EUR | 106.04% |
| 2012 FY | -7.72 Million EUR | 16.88% |
| 2011 FY | -9.29 Million EUR | -53.36% |
| 2010 FY | -6.06 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | 69.302% |
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | 186.914% |
| Vetoquinol SA | -129.83 Million EUR | 85.733% |
| Valneva SE | 82.73 Million EUR | 122.389% |
| AB Science S.A. | 13.03 Million EUR | 242.11% |
| Nanobiotix S.A. | -29.8 Million EUR | 37.839% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | -6636.0% |
| BioSenic S.A. | 28.04 Million EUR | 166.053% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 90.572% |
| Formycon AG | 2.45 Million EUR | 855.773% |